News | January 29, 2022
DCGI approves Bharat Biotech’s Phase 3 trials for intranasal vaccine
Intranasal vaccines are easier to administer in mass immunisation campaigns and help reduce or stop transmission
Intranasal vaccines are easier to administer in mass immunisation campaigns and help reduce or stop transmission
Company to manufacture drug substance for clinical supply of HaemaLogiX’s lead multiple myeloma drug candidate, KappaMab, at its new state-of-the-art facility in Guangzhou, China
The long-term partnership aims to make fermentation-based biotin available for the full range of relevant applications as a sustainable, non-chemical, European-sourced alternative
Acquisition adds Adaptate’s novel antibody-based ?? T-cell engager platform to Takeda’s Immuno-oncology portfolio built around the Innate Immune System
EMBER500RNA Prestain Loading Dye allows single-step denaturing, loading, and bright RNA staining on regular agarose gels
It has also been granted permission to conduct trials for booster dose
BPZE1 is the most advanced next-generation pertussis vaccine currently in clinical development
He has over 22 years of experience in pharmaceutical sales & business development
The revolutionary new nano coating is easy to apply and rejects liquid-based contagions like COVID-19/SARS-CoV-2 and variants, influenzas, and rhinoviruses and is available via ready-to-use sprays or pre-treated air filters
Oravax's vaccine technology is highly scalable for manufacturing and is easily transferable for wide scale logistical distribution, as there is no need for freezer storage
Subscribe To Our Newsletter & Stay Updated
